Trametinib has been approved for treatment of advanced BRAF-mutant melanoma, non-small cell lung cancer, anaplastic thyroid carcinoma [50,51,52], and multiple clinical studies are examining trametinib-based combinations in a variety of tumor types including melanoma and other tumors with NRAS-ERK pathway activation [53] (https://clinicaltrials.gov). Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.